



(86) Date de dépôt PCT/PCT Filing Date: 1999/11/01

(87) Date publication PCT/PCT Publication Date: 2000/05/11

(45) Date de délivrance/Issue Date: 2009/08/11

(85) Entrée phase nationale/National Entry: 2001/04/26

(86) N° demande PCT/PCT Application No.: JP 1999/006076

(87) N° publication PCT/PCT Publication No.: 2000/026250

(30) Priorité/Priority: 1998/10/30 (JP10/311408)

(51) Cl.Int./Int.Cl. *C07K 14/47* (2006.01),
A61K 38/17 (2006.01), *A61K 39/395* (2006.01),
C07K 16/18 (2006.01), *C12N 15/12* (2006.01),
C12N 9/12 (2006.01)

(72) Inventeurs/Inventors:

ARAI, KENICHI, JP;
MASAI, HISAO, JP


(73) Propriétaire/Owner:

JAPAN SCIENCE AND TECHNOLOGY AGENCY, JP

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : PROTEINES HUMAINES H37 ET ADNC LES CODANT

(54) Title: HUMAN H37 PROTEINS AND cDNAs ENCODING THE SAME



Dbf4 motif-N

H37 32: LKTDNMFLEKSKCRPLWGVKVEYLDPSVTTSEKLOKDTKDI GGRVEEFLSKDISYLTSNKK 91
mu-H37 : LKADNMFLEKSNYPKPLWGVKVEYLDPSVTTSEKLOKDTKDI GGRVEEFLSKDISYFVSNKK
Dm-H37 : TPPKVVKVTKSK-RPLCHFKVEYLDPSVTTSEKLOKDTKDI GGRVEEFLSKDISYFVSNKK

huDbf4N 92: EAKFAQT 98
muDbf4N : EAKFAQT
DmDbf4N : EVIGGTS

Dbf4 motif-C

H37 263: KQTGVKLRIQTDGDKYGGTSIQQLQKKEKKKGYCEGGLQKYEDLETHLSEKIRNFAQSN 322
mu-H37 : KQAGPKLRINMDGDKC-GTPVQLQKKEKKKGYCEGGLQKYEDLETHLSEKIRNFAQSN
Dm-H37 : PSLQELKKQSAIPNSPRSNCREPIDSSKQGGVCEIGKLEYDITNDHLQSKDHELFKNK
Dbf4 619: KSTSTNVTLHFNAQTACTAQPVKKETVKNNGYCHNCRVKYESLQHIIVSEKHLSEAE-N 677

(57) Abrégé/Abstract:

This application provides human H37 protein having an amino acid sequence of SEQ ID NO: 1 or NO: 2; human gene encoding the protein; cDNA of the human gene which has a base sequence of SEQ ID NO: 3 or NO: 4; DNA fragment comprising a partial

(57) **Abrégé(suite)/Abstract(continued):**

sequence of the cDNA; recombinant vector having the cDNA; antibody against human H37 protein; and a method for controlling the proliferation of cells by introducing the above DNA or antibody into the cells.

ABSTRACT

This application provides human H37 protein having an amino acid sequence of SEQ ID NO: 1 or NO: 2; human gene encoding the protein; cDNA of
5 the human gene which has a base sequence of SEQ ID NO: 3 or NO: 4; DNA fragment comprising a partial sequence of the cDNA; recombinant vector having the cDNA; antibody against human H37 protein; and a method for controlling the proliferation of cells by introducing the above DNA or antibody into the cells.

DESCRIPTION

Human H37 proteins and cDNAs encoding the Same

5

Technical Field

This application relates to human H37 protein and to cDNA encoding the protein. More particularly, this application relates to human H37 protein that is
10 an activity-controlling subunit for the protein Cdc7 controlling the replication of human cells; to human gene encoding the protein; to an antibody to the H37 protein; and to a method for controlling the proliferation of human cells using such genetic engineering material and antibody.

15

Background Art

Proliferation of cells is initiated when a liquid factor called a growth factor is bound to the receptor on the cell surface and a signal for proliferation is
20 transmitted into the cell. Accordingly, for an artificial induction of proliferation of incubated cells, methods where an excessive amount of a growth factor is added to a cell medium, where a receptor which is not inherently owned by the said cell is expressed on the cell surface and a factor which is specific for the receptor is added to a medium, etc. have been carried out. Further, in suppressing the cell
25 proliferation, methods where competing molecule, antagonist or the like to the receptor protein is added to the medium to suppress the binding of the receptor to the growth factor, etc. have been carried out.

On the other hand, in the case of the cell where a proliferation signal is
30 issued by binding of the receptor to the growth factor, a cycle in which its genomic DNA is replicated, uniformly distributed to daughter cells and then divided is repeated. Such a cycle is called "cell cycle" especially for eukaryotes. The cell

cycle is basically classified into four phases. Thus, S phase when chromosomal DNA is replicated; M phase when the replicated chromosome is divided by a spindle body and then cytoplasm is divided; G1 phase which is a period from M phase finishes until S phase begins; and G2 phase which is a period from S phase finishes until M phase starts. Transition from G1 phase to S phase is particularly strictly controlled and DNA replication takes place only once in S phase.

It has been confirmed from the studies in yeast and higher eukaryotic cells that cyclin-dependent kinase plays a critical role in the cell cycle progression (Nature 292:558-560, 1981; Cell 66:731-742, 1991; Nature 349:338-393, 1991; Science 257:1958-1961, 1992; Bioassays 17:471, 1995). Further, from a genetic analysis in yeast, it has been clarified that another serine/threonine kinase plays an essential role in the initial stage of S phase (G1/S transition). Thus, characterization of cdc7 mutation which was isolated as one of the cell division cycle mutants (J. Mol. Biol. 59:183-194, 1971), it revealed that the Cdc7 protein kinase functions immediately prior to chromosomal replication and that, during S phase, that is necessary for activation of origins (Mol. Cell Biol. 6:1590-1598, 1986; Genes Dev. 15:480-490, 1998; Genes Dev. 15:491-501, 1998). It has been also clarified that the Cdc7 kinase activity is dependent upon the presence of a regulatory subunit, Dbf4 (Genetics 131:21-29, 1992; Mol. Cell Biol. 13:2899-2908, 1993). Expression of Dbf4 is periodic and is regulated by both at the transcriptional and post-translational levels (Exp. Cell Res. 180:419-428, 1989). The increase in Cdc7 kinase activity at the G1/S boundary is at least accounted for by the elevated expression of Dbf4 in late G1 phase (Mol. Cell Biol. 13:2899-2908, 1994; Exp. Cell Res. 180:419-428, 1989). In addition, since Dbf4 interacts with replication origins in vivo (Science 265:1243-1246, 1994), it has been suggested that the Cdc7 may trigger S phase by directly activating the replication initiation complex assembled at the origins.

In addition, the inventors of this application had already isolated kinases related to yeast Cdc7 from *Schizosaccharomyces pombe*, *Xenopus*, mouse and human (J. Biol. Chem. 273:23248-23257, 1998; EMBO J. 16:4340-4351, 1997;

EMBO J. 14:3094-3104, 1995), and pointed out that eukaryotic chromosomal replication is regulated by a conserved mechanism involving this family of kinase.

From the findings in yeast and higher eukaryotes as mentioned above, it is expected that an artificial control of the cell proliferation is possible by means of the regulation of the Cdc7 kinase activity in cells, which is entirely other means than conventional methods using operation of growth factor/receptor binding.

However, the inventors had also found that the putative human homolog of Cdc7, huCdc7, possesses only a very low level of kinase activity when overexpressed in mammalian cells while a baculovirus expressed form of huCdc7 is inactive.

Under such circumstances, the inventors of this application have investigated a human cDNA library with a presumption of the presence of a regulatory subunit for human Cdc7, succeeded in isolating the cDNA encoding a novel protein which regulates the kinase activity by binding to huCdc7 and named the said protein encoded in this cDNA as H37 protein.

An object of the invention is to provide the novel protein obtained by the inventors in an industrially applicable form.

Another object of the invention is to provide a human gene encoding the protein and to provide a material for genetic operation including cDNA derived from the gene, an antibody to the protein.

Still another object of the Invention is to provide a method for the artificial control of proliferation of human cells using the above material for genetic operation.

Disclosure of the Invention

This application provides human H37 protein having an amino acid sequence of SEQ ID NO: 1 or NO: 2.

5

This application also provides human H37 protein having an amino acid sequence where one or more amino acid residue(s) in the amino acid sequence of SEQ ID NO: 1 or NO: 2 is/are deleted therefrom, substituted therefor or added thereto.

10

This application further provides a human gene encoding the above-mentioned human H37 protein; cDNA of said human gene which has a base sequence of SEQ ID NO: 3 or NO: 4; and DNA fragment comprising a partial sequence of those cDNAs.

15

This application furthermore provides a recombinant vector having the above-mentioned cDNA and an antibody against the human H37 protein.

20

This application still further provides a method for promoting the proliferation of cells, which comprises introducing the above-mentioned cDNA or the DNA fragment together with expression regulatory sequence into cell, and a method for suppressing the proliferation of cells, which comprises introducing the above-mentioned antibody into the cell.

25

Brief Description of Drawings

Fig. 1 is the result of a western blotting measuring the coimmunoprecipitation of H37 with huCdc7 expressed in mammalian cells. Lanes 1-4, immunoprecipitates; lanes 5-7, whole cell extract. Upper and middle panels, immunoprecipitated with anti-huCdc7 antibody No. 1; lower panel, immunoprecipitated with anti-myc antibody. Extracts were prepared from Cos7

30

cells transfected with huCdc7 in combination with H1 (lanes 2 and 5), H18 (lanes 3 and 6), H37 (lanes 4 and 7) or huCdc7 alone (lane 1). Western blotting was conducted with anti-myc antibody (upper panel) or an anti-huCdc7 antibody No.1 (middle and lower panel).

5

Fig. 2 is a result of the western blotting measuring antibodies against H37 protein and association of huCdc7 and H37 *in vivo*. Nuclear extracts prepared from Cos7 cells transfected with myc-tagged H37 cDNA were blotted with anti-H37C (lane 1), anti-H37N (lane 2), anti-H37Cpep (lane 3) or anti-myc (lane 4) antibody. The arrow indicates the myc-tagged H37 protein, which carries 63 amino acids derived from 5' non-coding region in addition to the myc-tag. Immunoprecipitations from CEM extracts using either anti-huCdc7Cpep (lanes 5 and 6) or anti-H37Cpep (lanes 7 and 8) were separated on gel electrophoresis and blotted with huCdc7 monoclonal antibody (4A8). The symbols - and + indicates absence and presence, respectively, of each antigen peptide during immunoprecipitation. Lanes 9-13; immunoprecipitates, prepared from nuclear extracts of HeLa cells by anti-huCdc7 No.1 (lane 9), anti-huCdc7 monoclonal antibody 4A8 (lane 10), anti-H37C (lane 11), anti-H37N (lane 12) or anti-H37Cpep (lane 13), were blotted with anti-H37Cpep.

20

Fig. 3 shows the result of immunoprecipitation by the use of anti-huCdc7 antibody No.1 (lanes 1-5) or anti-myc antibody (lanes 6-10) from the extract of Cos7 cells transfected with myc-tagged H37 alone (lanes 1 and 6), or together with wild-type huCdc7 (lanes 2 and 7), or kinase negative huCdc7 (lanes 3 and 8). Wild-type huCdc7 alone (lanes 4 and 9) and kinase negative huCdc7 alone (lanes 5 and 10) were included as control.

25

Fig. 4 shows mobility shift of H37 induced by coexpression of wild-type huCdc7. Extracts were prepared from Cos7 cells expressing either wild-type or kinase negative huCdc7 together with myc-tagged H37. Immunoprecipitates with anti-huCdc7 antibody No. 1 (lanes 1 and 2) or anti-myc antibody (lanes 3 and 4) were blotted with anti-myc antibody (upper) or anti-huCdc7 antibody (lower).

30

In all cases, samples were run on 8% SDS-PAGE.

Fig. 5 shows an amino acid sequence of the full-length H37 protein which is as same as the SEQ ID NO: 1.

5

Fig. 6 shows schematic representation of conserved regions between Dbf4 and H37. The double-arrowed region on Dbf4 was reported to be sufficient for interaction with huCdc7. Solid and gray double-arrowed region on H37 indicates the portion essential for interaction with huCdc7 or that sufficient for activation of huCdc7 kinase activity, respectively.

10

Fig. 7 is a schematic representation of N-terminal and C-terminal deletion derivatives of H37 proteins. The number at the end of each bar indicates the portion of the amino acid (corresponding to SEQ ID NO: 1) at the deletion endpoint. The striped region indicates Dbf4 motif-C.

15

Fig. 8 shows lacZ activity of H37 deletion derivatives in two-hybrid assay with huCdc7.

20

Fig. 9 shows the result of antibody coprecipitation method in which H37 deletion derivatives and huCdc7 were co-expressed in COS7 cells and a complex formation was measured.

25

Fig. 10 (a) is the result of northern analysis of H37 mRNA expression in various tissues, and (b) is the result of a northern analysis of H37 mRNA expression in various cancer cell lines.

30

Fig. 11 shows the results where WI38 cells in a resting phase are stimulated by addition of 10% of serum and DNA contents at various stages were analyzed by means of FACS.

Fig. 12 shows the result of northern analysis of H37 and huCdc6

expression by using RNA extracted from cells of Fig. 11 (upper), and the graphs showing the relative expression amount of each mRNA (middle and lower).

Fig. 13 shows graphs showing each cell cycle fraction of human CEM cells
5 fractionated by an elutriation method.

Fig. 14 shows the result of northern analysis for expression of H37 and cyclin E in each fraction of Fig. 13 (upper), and also shows the graphs showing the relative expression amounts of each mRNA (middle and lower).
10

Fig. 15 shows the result of FACS analysis for DNA content in which HeLa cells were stopped at latter G2 phase using nocodazole and then the cell cycle was synchronously shifted.

Fig. 16 shows the result northern analysis for expression of H37 and cyclin E in each cell cycle of Fig. 14 (upper), and also shows the graphs showing the relative expression amounts of each mRNA (middle and lower).
15

Fig. 17 shows H37 localization in cells measured by indirect
20 immunofluorescent technique. The antibodies used are anti-H37C (A), anti-H37N (C) and a control antibody (E) while B, D and F were pictures stained with DAPI.

Fig. 18 shows kinetics of induction of DNA replication after serum stimulation of KD cells as measured by BrdU incorporation.
25

Fig. 19 shows the results in which KD cells, synchronized by serum starvation, were microinjected with various antibodies at 12 hours after serum stimulation, and then the rate of the cells incorporating the BrdU after 16 hours was measured. The numbers show the rate of the cells which are conducting the
30 DNA synthesis.

Fig. 20 is microscopic pictures of examples of cells into which a mixture of

anti-H37Cpep antibody and antigen peptide was microinjected. The pictures show the incorporated BrdU (upper), injected antibody (middle) and cells (lower).

5

Best Mode for Carrying Out the Invention

The human H37 protein of this invention has the amino acid sequence of SEQ ID NO: 1 and is a protein molecule encoded in the sequence region from 518th to 2541st of cDNA whose base sequence is shown in SEQ ID NO: 3. The
10 H37 protein of this invention also has the amino acid sequence of SEQ ID NO: 2 and is a protein encoded in the sequence region from 518th to 1222nd of cDNA whose base sequence is shown in SEQ ID NO: 4. SEQ ID NO: 3 and NO: 4 are cDNAs derived from mRNA transcribed from the same genomic gene but the cDNA of SEQ ID NO: 4 is in a different splicing form from SEQ ID NO: 3, and there is a
15 deletion from 1199th to 1259th of SEQ ID NO: 3.

Those H37 proteins can be prepared by known methods such as isolation from human organs and cell lines, chemical synthesis of peptide based upon the amino acid sequence provided by this invention, and a recombinant DNA
20 technique using cDNA fragments provided by this invention. For example, in case the H37 protein is prepared by means of a recombinant DNA technique, RNA is prepared from a vector having the cDNA fragment of this invention by an in vitro transcription and then an in vitro translation is carried out using the above as a template whereby an expression in vitro is possible. In addition, when the
25 translational region is recombined to a suitable vector by a known method, it is possible to express the H37 protein encoded in cDNA in a large quantity in Escherichia coli, Bacillus subtilis, yeast, insect cells, animal cells, etc.

When the human H37 protein of this invention is expressed in a
30 microorganism such as E. coli, the translational region of cDNA of this invention is inserted into an expression vector having, for example, promoter, ribosome binding site, cDNA cloning site, terminator, origin replicable in microorganism, etc.

whereupon a recombinant expression vector is prepared, then host cell is transformed using the said expression vector and the resulting transformant is incubated whereupon H37 protein encoded in cDNA can be produced in a microorganism in a large quantity. Alternatively, it can be expressed as a fusion protein with other protein. The resulting fusion protein is cleaved by an appropriate protease whereupon only the protein portion encoded in cDNA can be obtained.

When the human H37 protein of this invention is expressed in animal cells, the translational region of cDNA of this invention is recombined with expression vector for animal cells having, for example, promoter, poly(A) addition site, and splicing site, and then introduced into the animal cells whereupon the H37 protein of this invention can be expressed in animal cells.

The human H37 protein obtained by the method as mentioned above can be used as an antigen for the preparation of antibody for suppressing the proliferation of cells through inhibition of the kinase activity of huCdc7.

In addition, as will be confirmed by the Examples later, the human H37 protein of this invention has almost no similarity in terms of structure to cyclins which have been elucidated up to now, but it may be regarded as a cyclin-like associating factor for huCdc7 kinase in such respects that its expression is regulated by a cell cycle and that, as a result of binding to an huCdc7 catalytic subunit, its kinase activity can be activated. Accordingly, since the H37 protein is believed to be a very important target factor in a signal transduction pathway for the cell proliferation induced by a growth factor, elucidation of how the expression of the H37 protein or activity thereof is regulated by the signal of cell cycle in G1/S phases is expected to provide a big and novel finding for clarifying the molecular mechanism of cell cycle control of cell replication in animal cells.

30

The human H37 protein of the invention contains peptide fragments (five or more amino acid residues) containing any partial amino acid sequence of SEQ

ID NO: 1 or NO: 2. Such peptide fragments can be also used as an antigen for the preparation of antibody.

5 The gene of the invention is a human gene encoding the above-mentioned human H37 protein and can be isolated from known genomic libraries using, for example, the cDNA of this invention or a partial sequence thereof as a probe.

10 The cDNA of the invention is characterized in having a base sequence of SEQ ID NO: 3 or NO: 4, and can be cloned, for example, from cDNA libraries derived from human cells. cDNA is synthesized using poly(A)⁺ RNA extracted from human cells as a template. The human cells may be either those excised from human body by a surgical operation or cell lines. The cDNA can be prepared by known methods such as Okayama-Berg method (Okayama, H and Berg, P., Mol. Cell. Biol., 2:161-170, 1982), Gubler-Hoffmann method (Gubler, U. and Hoffman, J. Gene, 25:263-269, 1983) and Capping method (Kato, S. et al., Gene, 150:243-250, 1994).

20 The human H37 protein of the invention is expressed in any tissue except brain and kidney and, therefore, when the human cDNA library prepared from human cells is screened using an oligonucleotide probe synthesized based on the base sequence of cDNA in SEQ ID NO: 3 or NO: 4, it is possible to easily prepare the same clone of the invention. It is also possible that the desired cDNA is synthesized by a polymerase chain reaction (PCR) using such an oligonucleotide as a primer.

25

In general, polymorphism due to the difference among individuals is frequently noted in human gene. Accordingly, cDNA of SEQ ID NO: 3 or NO: 4 where one or more nucleotide(s) is/are added thereto and/or deleted therefrom and/or other nucleotide(s) is/are substituted therefor is also covered by the invention.

30

Similarly, the protein where one or more nucleotide(s) is/are added

thereto and/or deleted therefrom and/or other nucleotide(s) is/are substituted therefor as a result of those modifications is also covered by the invention so far as it has an activity of the protein having an amino acid sequence of SEQ ID NO: 1 or NO: 2. Further, variant protein where one or more nucleotide(s) is/are added thereto and/or deleted therefrom and/or other nucleotide(s) is/are substituted by an artificial means is covered by this invention as well.

The DNA fragment of the invention covers a cDNA fragment (10 bp or more) containing any partial base sequence of SEQ ID NO: 3 or NO: 4, or a cDNA fragment comprising an antisense strand thereof.

Antibody against human H37 protein of the invention can be prepared as a polyclonal antibody or a monoclonal antibody by a known method using protein per se or a partial peptide thereof.

A method for promoting the cell proliferation according to the invention is carried out by such a manner that a recombinant DNA comprising the cDNA having a base sequence of SEQ ID NO: 3 or NO: 4, or comprising a partial sequence thereof (such as a DNA fragment encoding 419 amino acid sequence region at the C terminal as shown in Example 3) and an expression-regulatory sequence (promoter and/or enhancer sequence for animal cells) is introduced into animal cells whereby the H37 protein having an amino sequence of SEQ ID NO: 1 or NO: 2 is excessively expressed in cell nuclei. Introduction of the recombinant DNA into cells can be carried out by a known method such as a calcium phosphate method, a method where ribosome and erythrocyte ghost are used, an electroporation method, a method where retrovirus or adenovirus is used as a vector and a microinjection method using a glass pipette. Promotion of cell proliferation as such is useful, for example, in a large-scale preparation of the stem cell that is useful for the therapy of human diseases. Stem cells can be differentiated into other kinds of cells such as blood stem cell and nerve stem cell, and are able to produce a large number of cells of different cell type that constitute the human body. Therefore, transplantation of stem cell in the diseases such as

leukemia is a very important therapeutic means. However, since no liquid factor for self-proliferation of human stem cells without differentiation has been identified yet, the preparation of stem cells in an amount sufficient for the therapy has not been easy. According to the method of this invention, it could be possible that, as a result of manipulating the proliferation program in stem cells, the stem cells can be unlimitedly self-replicated and self-proliferated in vitro. In addition, such a promotion of cell proliferation in vitro could be also useful for the preparation of a large quantity of cells for introduction of gene for genetic therapy by ex vivo means.

10

The method for the suppression of cell proliferation according to the invention is carried out by injecting the above-mentioned antibody into cells. Alternatively, it may be carried out by inhibiting the expression of the cell-intrinsic H37 protein gene as well. An example thereof is a method where DNA encoding the ribozyme sequence or the antisense sequence to the transcript of the gene is introduced into the cells. Suppression of the cell proliferation as such is expected to provide a novel means for suppressing an excessive proliferation of cancer cells for example.

20

Examples

The invention will now be further illustrated by way of the following examples although the invention is not limited to those examples.

25

Example 1.

H37 cDNA labeled with a Flag tag was ligated to the down stream of an SRalpha promoter and introduced into IL-3 (interleukin 3)-dependent proB cell, Ba/F3, to give a stable transformant cell line constitutively expressing the Flag-tagged H37 protein. In this cell line, rate of the cell at the late S phase or G2

30

phase where DNA synthesis was almost finishing or was finished in the population of the proliferating cells increased as compared with the control parental cell line. On the other hand, the parental cells stopped its proliferation by removal of IL-3 and came into G0 phase but, in the stable transformant cell line, rate of the cells existing in S phase significantly increased even after the removal of IL-3. This result shows that the constitutive production of the H37 protein promotes the shift from G0/G1 phase to S phase, or the progress of S phase itself. It also suggests that the progress of cell cycle can be operated by an artificial expression of the H37 protein or a derivative thereof.

10

Example 2.

cDNA library of HeLa cell was prepared using a pGAD-GH vector and each vector was introduced into yeast strain CG1945 that has a recombinant plasmid with huCdc7 fused to DNA-binding domain of Gal4. As a result of a screening of about 3×10^5 cells of transformed yeast, five clones where β -galactosidase was positive were obtained. DNA base sequence of the insert was determined and the database was searched whereupon all of them were novel cDNA. Among them, three clones were same having a base sequence of SEQ ID NO: 1. This cDNA was named H37. Other two were single clones and were named H1 and H18, respectively.

The interaction of huCdc7 with protein encoded in those positive clones was further investigated using a production increase system in animal cells. Thus, each expression plasmid of H1, H18 and H37 tagged with myc epitope was transfected to animal cell Cos7 together with a full-length huCdc7 expression plasmid. The result is as shown in Fig. 1. Although the H37 protein was coimmunoprecipitated with an antibody against huCdc7, H1 and H18 proteins were not coprecipitated (cf. lanes 2-4 of the upper panel, Fig. 1). On the contrary, huCdc7 was coimmunoprecipitated by using anti-myc antibody alone in the case of the cells where myc-tagged H37 is co-expressed (cf. lane 4 of the lower lane, Fig.

25
30

1). From those results, it has been confirmed that only H37 cDNA encodes a protein efficiently interacting with huCdc7.

Then, in order to investigate the intrinsic H37 protein, each antibody
5 against N- or C-terminal regions of H37 (anti-H37N antibody or anti-H37C
antibody) was prepared. Further, antibody against C-terminal oligopeptide of
H37 (anti-H37Cpep antibody) and antibody against C-terminal oligopeptide of
huCdc7 (anti-huCdc7Cpep antibody) were also prepared. After that, association
of each antibody with intrinsic huCdc7 and H37 in cells was measured. The
10 result is as shown in Fig. 2. Thus, all of the antibodies to H37 specifically react
with the myc-tagged H37 protein of 90 kDa expressed in Cos7 cells (cf. lanes 1-4,
Fig. 2). Complex prepared from human CEM cells was able to be coprecipitated
using an affinity-purified anti-peptide antibody. It was confirmed by an
immunoblotting using anti-huCdc7Cpep antibody that all of huCdc7 and H37
15 immunoprecipitates contained huCdc7 (lanes 5 and 7, Fig. 2). This interaction of
H37 with huCdc7 completely disappeared when antibody and peptide used as
antigen for preparing the antibody were subjected to a pre-incubation in advance
(cf. lane 8, Fig. 2). In extracts of HeLa cells, both anti-Cdc7 antibody and
anti-H37 antibody were able to coprecipitate one polypeptide of 80 kDa that
20 specifically reacted with anti-H37 antibody (lanes 9-13, Fig. 2).

From the above result, it was found that intrinsic huCdc7 and H37
protein were present in cells as a complex.

25

Example 3.

In order to investigate whether H37 protein has an ability of activating
huCdc7, huCdc7/H37 complex prepared by expression of myc-tagged H37 and
30 wild-type or kinase negative huCdc7 in Cos cells was immunoprecipitated by
anti-huCdc7 antibody or anti-myc antibody and then a kinase reaction in vitro
was measured using GST-MCM3 fusion protein as a substrate. The result is as

shown in Fig. 3 and in Fig. 4. In the presence of wild-type huCdc7, phosphorylation in a good efficiency was observed for the MCM3 protein in both immunoprecipitate of anti-huCdc7 antibody and immunoprecipitate of anti-myc antibody (cf. lanes 2 and 7, Fig. 3). Further, two more phosphorylated proteins
5 were observed and they were identified as transfected huCdc7 and myc-tagged H37 (data not shown). Since the phosphorylation as such was not detected at all in kinase negative huCdc7, it was confirmed that kinase activity of huCdc7 acted in the phosphorylation. However, kinase negative huCdc7 was also able to form a complex with H37 protein (cf. lanes 3 and 8, Fig. 3; lanes 2 and 4, Fig. 4). In
10 addition, the mobility of H37 protein on gel electrophoresis was slow when a wild-type huCdc7 was co-expressed and detected as plural bands while such a shift was not observed in kinase negative huCdc7 (cf. lanes 1 and 3, Fig. 4). The band where the mobility was slow disappeared by a treatment with phosphatase and, therefore, it was confirmed to be a perphosphorylated H37 protein (data not
15 shown). In addition, when huCdc7 and H37 protein were co-expressed in insect cells, it was possible to reconstitute a very strong kinase activity which was able to efficiently phosphorylate MCM2 and MCM3 proteins (data now shown).

The above result shows that H37 protein activates huCdc7 kinase and
20 further that H37 protein itself is phosphorylated by huCdc7.

Further, under those experimental conditions, intrinsic H37 protein level was too low and in the case where only huCdc7 catalytic subunit was expressed and, therefore, the kinase activity was little (cf. lanes 4 and 9, Fig. 3). From those
25 facts, it was confirmed that H37 protein encoded regulatory cell unit of huCdc7 and specifically activated its kinase activity.

Example 4.

30

An amino acid sequence of the H37 protein (SEQ ID NO: 1) was analyzed. The result was that, as shown in Fig. 5 and Fig. 6, an amino acid sequence region

having a homology of 33% with budding yeast Dbf4 was found. This conserved domain (H37 motif C) was also present in the gene similar to H37 identified in mouse, fruit fly and fission yeast (cf. Fig. 6). Further, another amino acid sequence of H37 (H37 motif N) was conserved in the H37-related gene in mouse,
 5 fruit fly and fission yeast. However, the H37 motif N was conserved in a somewhat modified form on the Dbf4 protein of a budding yeast (cf. Fig. 6; data partially not shown).

In order to determine the region on H37 protein essential for binding with
 10 huCdc7, a series of deletion derivatives of H37 at N- and C-terminals as shown in Fig. 7 was prepared, each of them was expressed in yeast as a fusion protein with Gal4 activated domain and an interaction of each deletion derivative with huCdc7 was investigated by means of a two-hybrid assay. The result is as shown in Fig. 8. As a result of deletion at N-terminal, even a deletion of 255 amino acids at
 15 N-terminal did not affect the interaction with huCdc7 ($\Delta N2$). However, when 50 amino acids at N-terminal were further deleted whereupon the H37 motif C was deleted, an interaction with huCdc7 was completely lost ($\Delta N3$).

On the other hand, with regard to deletion from C-terminal, when only 20
 20 amino acids were deleted, the binding ability with huCdc7 decreased to an extent of about 60% (ΔC). In addition, when 243 or 369 amino acids were deleted from the C-terminal ($\Delta P2$ and ΔB), the interaction lowered to an extent of about 10% of the full-length clone. $\Delta P1$ containing only 235 amino acids of N-terminal did not interact with huCdc7. However, 50 amino acids that were commonly present in
 25 ΔB and $\Delta N2$ were not sufficient for an efficient interaction with huCdc7 (data not shown).

A part of the above-mentioned H37 deletion derivatives was co-expressed in COS7 cells together with huCdc7 and it was confirmed by immunoprecipitation
 30 method whether it formed a complex with huCdc7 protein. The result was that, like in the result of a two-hybrid assay, it was confirmed that only H37 deletion derivatives of ΔB and $\Delta N2$ formed a complex with huCdc7 (cf. Fig. 9).

The above result shows that H37 motif-C is essential for an interaction of H37 protein with huCdc7 catalytic subunit but shows that H37 motif C alone is insufficient. In the budding yeast, it was reported already that the region containing H37 motif C was sufficient for binding with Cdc7 (Mol. Cell. Biol. 15:6775-6782, 1996). When an in vitro kinase reaction was carried out using those deletion derivatives, it was found that, although the extent was weak, only 419 amino acids at the C-terminal containing Dbf4 motif-C was sufficient for activation of phosphorylating ability of huCdc7 (data not shown).

10

Example 5.

Expression patterns of H37 mRNA in various human tissues and cancer cells were investigated by northern blotting. The result is as shown in Fig. 10 (a) and (b). By an H37 cDNA-specific probe, a transcribed product of 2.5 kb was detected in all tissues except brain and kidney and also in all cancer cells. That was contrary to the fact that, in brain and kidney, huCdc7 mRNA was relatively highly expressed (EMBO J. 16:4340-4351, 1997). Among the tissues tested, expression of H37 mRNA was highest in testicles and then in thymus, and it was reported by the inventors already that both of them were the tissues where the expression of huCdc7 catalytic subunit was particularly high as well (EMBO J. 16:4340-4351, 1997). In the testicles, two different RMA bands of 6 kb and 4 kb were also detected (cf. Fig. 10 (a)) although it was ambiguous what the real substances therefor were. It was also confirmed that H37 mRNA was expressed in a very high level in nearly all cancer cells except lung cancer cell A549 (cf. Fig. 10 (b)). That shows an important role of H37 protein in the cells having an active proliferating ability.

30

Example 6.

In order to investigate whether expression of H37 was regulated by cell cycle, human normal fibroblast cell WI38 was synchronized with G0 phase by means of serum starvation (cf. Fig. 11), total RNA was prepared at various periods after addition of serum and the level of H37 mRNA was investigated by northern blotting. The result is as shown in Fig. 12. H37 mRNA level was low in the cell at the resting stage and, as the cells came near the boundary of G1 and S, it gradually increased and, after 20 hours from the serum addition, it became maximum. The expression pattern shown in Fig. 12 was similar to that of transcribed product of huCdc6 that is known to be induced by growth stimulation (Mol. Cell. Biol. 15:4215-4224, 1995; Proc. Natl. Acad. Sci. USA 94:142-147, 1997).

Further, in order to investigate the changes in expression of H37 in cell cycle, human CEM cells were fractionated by means of elutriation method (cf. Fig. 13) and then a northern blotting was carried out (cf. Fig. 14). It was shown by the result thereof that H37 mRNA was low at G1 phase, increased from the late G1 phase to S phase, highly maintained during S phase and somewhat decreased in G2 phase although it was still kept high. In an experiment where HeLa cells were stopped at G2 phase by nocodazole and the cell cycle was synchronously shifted (cf. Fig. 15), it was also found that H37 mRNA decreased together with shift from G2 to G1 and increased again at shift to S phase (cf. Fig. 16). Similarly, expression of Cdc6 rose together with shift from G1 phase to S phase but there was a difference from H37 in that, as S phase proceeded, it decreased and, at G2 phase it was suppressed to low. The result shows that the expression of H37 mRNA changes even in the proliferating cell cycle, becomes maximum at S phase where it functions and is kept high throughout S phase.

After that, in order to investigate the changes in H37 protein and huCdc7 kinase activity depending upon H37 in cell cycle, amount of H37 protein in K562 cells synchronized with nocodazole was analyzed by western analysis while Cdc7 kinase activity was analyzed by phosphorylation reaction of GST-huMCM2 protein using anti-huCdc7 immunoprecipitate in the same manner as in Fig. 15.

Although H37 protein was not detected from G1/M boundary to G1 phase, it started to be detected at the G1/S boundary and detected throughout S phase. This was in contrast to the fact that cyclin E protein is detected already in G1 phase and, as S phase proceeds, the amount suddenly decreases. On the other hand, huCdc kinase activity was also detected in S phase only corresponding to the level of H37 protein. Further, H37 protein was detected as plural phosphorylated bands in S phase and was thought to be phosphorylated by huCdc7 that was probably associated. On the contrary, level of huCdc7 protein was almost constant throughout cell cycle. This result proves that the level of huCdc7 protein varies in cell cycle and is kept high in S phase whereby huCdc7 kinase activity is also kept high in S phase.

In order to further investigate the expression of H37, intracellular localization of H37 protein in animal cells was measured. The result of indirect fluorescent antibody method using two kinds of H37-specific antibodies was that, in both HeLa and WI38 cells, intrinsic H37 protein was observed as very clear various spots in the nuclei (cf. Fig. 17).

When those results and the intranuclear localization of huCdc7 catalytic subunit already reported by the inventors (EMBO J. 16:4340-4351, 1997) were taken into consideration, it was confirmed that huCdc7/H37 complex was a kinase localized in the nuclei and that its regulatory subunit H37 was expressed depending upon the stage of cell cycle.

25

Example 7.

Function of the intrinsic H37 protein in the shift from G1 to S in cell cycle was investigated by antibody microinjection method. Antibody against N-terminal 305 amino acids of H37 protein (anti-H37N antibody) and antibody against C-terminal oligopeptide (anti-H37Cpep antibody) were treated by affinity purification and those antibodies were microinjected into normal fibroblast cells

19a

(KD cells) derived from human lip. KD cells were previously arrested at G0 phase by means of serum starvation and then synchronously proceeded in cell cycle by re-addition of serum. Numbers of the BrdU-positive cells, which BrdU is a nucleotide derivative and is incorporated into the cells, were measured whereby it was investigated how much fractions of cells at S phase were present after various stages after addition of serum. The result is as shown in Fig. 18. It was confirmed that the cells started DNA synthesis after about 18 hours from serum addition and that, after 24 hours, almost 90% of the cells were in S phase.

Accordingly, in this Example, antibody was microinjected at the period of after 12 hours after the addition of serum where the cells were still in G1 phase and, at 26 hours when cells would be of in S phase, the cells were fixed and the BrdU-positive cells were measured. The result is as shown in Fig. 19. Although 70% of the cells into which anti-H37N antibody was microinjected did not shift into S phase, there was nearly no effect by the control antibody. Even by the microinjection of the anti-H37Cpep antibody, an effect of inhibiting the shift to S phase which was same as or even more than the anti-H37N antibody was observed. In addition, when anti-H37Cpep antibody and a peptide which was an antigen for the preparation of anti-H37Cpep antibody were simultaneously microinjected into the cells, 70% or more of the cells were shifted to S phase.

Fig. 20 is a staining example of BrdU and microinjected antibody. The antibody was microinjected at the stage when the cells were from the mid to late S phase and, during that period, expression of H37 protein is believed to be low. The microinjected antibody efficiently bound to the freshly synthesized H37 protein and, as a result, it is speculated to inhibit the transfer of H37 protein into nucleus. Those results strongly suggest the function of H37, i.e. the function of huCdc7/H37 complex is required for the progression of S phase of the animal cells.

Industrial Applicability

As fully illustrated hereinabove, the present invention provided human H37 protein, a regulatory subunit for Cdc7 that regulate replication of human cells, human gene encoding this protein as well as cDNA thereof, an antibody against H37 protein, and a method for controlling the proliferation of human cells using those genetic engineering materials and antibody. As a result, it provides potentially novel means for preparation of the necessary amount of stem cells or the like to be used for the therapy of various human diseases or for the suppression of proliferation of cancer cells.

<110> Japan Science and Technology Corporation

<140> PCT/JP99/06067

<141> 1999-11-01

<150> JP No. 10-311408

<151> 1998-10-30

<160> 4

 $\langle 210 \rangle \quad 1$

<211> 674

<212> PRT

<213> Homo sapiens

<400> 1

Met 1	Asn	Ser	Gly	Ala 5	Met	Arg	Ile	His	Ser 10	Lys	Gly	His	Phe	Gln 15	Gly
Gly	Ile	Gln	Val 20	Lys	Asn	Glu	Lys	Asn 25	Arg	Pro	Ser	Leu	Lys 30	Ser	Leu
Lys	Thr	Asp 35	Asn	Arg	Pro	Glu	Lys 40	Ser	Lys	Cys	Lys	Pro 45	Leu	Trp	Gly
Lys	Val 50	Phe	Tyr	Leu	Asp	Leu	Pro 55	Ser	Val	Thr	Ile 60	Ser	Glu	Lys	Leu
Gln 65	Lys	Asp	Ile	Lys 70	Asp	Leu	Gly	Gly	Arg 75	Val	Glu	Glu	Phe	Leu	Ser 80
Lys	Asp	Ile	Ser	Tyr 85	Leu	Ile	Ser	Asn 90	Lys	Lys	Glu	Ala	Lys	Phe 95	Ala
Gln	Thr	Leu	Gly 100	Arg	Ile	Ser	Pro	Val 105	Pro	Ser	Pro	Glu	Ser 110	Ala	Tyr
Thr	Ala	Glu 115	Thr	Thr	Ser	Pro	His 120	Pro	Ser	His	Asp	Gly 125	Ser	Ser	Phe
Lys	Ser 130	Pro	Asp	Thr	Val 135	Cys	Leu	Ser	Arg	Gly	Lys 140	Leu	Leu	Val	Glu
Lys 145	Ala	Ile	Lys	Asp 150	His	Asp	Phe	Ile	Pro	Ser	Asn 155	Ser	Ile	Leu	Ser 160
Asn	Ala	Leu	Ser 165	Trp	Gly	Val	Lys	Ile 170	Leu	His	Ile	Asp	Asp 175	Ile	Arg
Tyr	Tyr	Ile 180	Glu	Gln	Lys	Lys	Lys 185	Glu	Leu	Tyr	Leu	Leu 190	Lys	Lys	Ser
Ser	Thr 195	Ser	Val	Arg	Asp	Gly	Gly 200	Lys	Arg	Val	Gly 205	Ser	Gly	Ala	Gln
Lys	Thr 210	Arg	Thr	Gly	Arg	Leu	Lys 215	Lys	Pro	Phe	Val 220	Lys	Val	Glu	Asp
Met 225	Ser	Gln	Leu	Tyr 230	Arg	Pro	Phe	Tyr	Leu	Gln 235	Leu	Thr	Asn	Met	Pro 240
Phe	Ile	Asn	Tyr 245	Ser	Ile	Gln	Lys	Pro 250	Cys	Ser	Pro	Phe	Asp 255	Val	Asp
Lys	Pro	Ser	Ser 260	Met	Gln	Lys	Gln 265	Thr	Gln	Val	Lys	Leu	Arg 270	Ile	Gln

Thr	Asp	Gly	Asp	Lys	Tyr	Gly	Gly	Thr	Ser	Ile	Gln	Leu	Gln	Leu	Lys	
		275					280					285				
Glu	Lys	Lys	Lys	Lys	Gly	Tyr	Cys	Glu	Cys	Cys	Leu	Gln	Lys	Tyr	Glu	
	290					295					300					
Asp	Leu	Glu	Thr	His	Leu	Leu	Ser	Glu	Gln	His	Arg	Asn	Phe	Ala	Gln	
305					310					315					320	
Ser	Asn	Gln	Tyr	Gln	Val	Val	Asp	Asp	Ile	Val	Ser	Lys	Leu	Val	Phe	
				325					330						335	
Asp	Phe	Val	Glu	Tyr	Glu	Lys	Asp	Thr	Pro	Lys	Lys	Lys	Arg	Ile	Lys	
			240					245					350			
Tyr	Ser	Val	Gly	Ser	Leu	Ser	Pro	Val	Ser	Ala	Ser	Val	Leu	Lys	Lys	
		355					360					365				
Thr	Glu	Gln	Lys	Glu	Lys	Val	Glu	Leu	Gln	His	Ile	Ser	Gln	Lys	Asp	
	370					375					380					
Cys	Gln	Glu	Asp	Asp	Thr	Thr	Val	Lys	Glu	Gln	Asn	Phe	Leu	Tyr	Lys	
385					390					395					400	
Glu	Thr	Gln	Glu	Thr	Glu	Lys	Lys	Leu	Leu	Phe	Ile	Ser	Glu	Pro	Ile	
				405				410						415		
Pro	His	Pro	Ser	Asn	Glu	Leu	Arg	Gly	Leu	Asn	Glu	Lys	Met	Ser	Asn	
			420					425					430			
Lys	Cys	Ser	Met	Leu	Ser	Thr	Ala	Glu	Asp	Asp	Ile	Arg	Gln	Asn	Phe	
		435					440					445				
Thr	Gln	Leu	Pro	Leu	His	Lys	Asn	Lys	Gln	Glu	Cys	Ile	Leu	Asp	Ile	
	450					455					460					
Ser	Glu	His	Thr	Leu	Ser	Glu	Asn	Asp	Leu	Glu	Glu	Leu	Arg	Val	Asp	
465					470					475					480	
His	Tyr	Lys	Cys	Asn	Ile	Gln	Ala	Ser	Val	His	Val	Ser	Asp	Phe	Ser	
				485					490					495		
Thr	Asp	Asn	Ser	Gly	Ser	Gln	Pro	Lys	Gln	Lys	Ser	Asp	Thr	Val	Leu	
			500					505					510			
Phe	Pro	Ala	Lys	Asp	Leu	Lys	Glu	Lys	Asp	Leu	His	Ser	Ile	Phe	Thr	
		515					520					525				
His	Asp	Ser	Gly	Leu	Ile	Thr	Ile	Asn	Ser	Ser	Gln	Glu	His	Leu	Thr	
	530					535					540					
Val	Gln	Ala	Lys	Ala	Pro	Phe	His	Thr	Pro	Pro	Glu	Glu	Pro	Asn	Glu	
545					550					555					560	
Cys	Asp	Phe	Lys	Asn	Met	Asp	Ser	Leu	Pro	Ser	Gly	Lys	Ile	His	Arg	
				565				570						575		
Lys	Val	Lys	Ile	Ile	Leu	Gly	Arg	Asn	Arg	Lys	Glu	Asn	Leu	Glu	Pro	
			580					585					590			
Asn	Ala	Glu	Phe	Asp	Lys	Arg	Thr	Glu	Phe	Ile	Thr	Gln	Glu	Glu	Asn	
		595					600					605				
Arg	Ile	Cys	Ser	Ser	Pro	Val	Gln									

20c

<210> 2

<211> 234

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Asn Ser Gly Ala Met Arg Ile His Ser Lys Gly His Phe Gln Gly
 1          5          10          15
Gly Ile Gln Val Lys Asn Glu Lys Asn Arg Pro Ser Leu Lys Ser Leu
          20          25          30
Lys Thr Asp Asn Arg Pro Glu Lys Ser Lys Cys Lys Pro Leu Trp Gly
          35          40          45
Lys Val Phe Tyr Leu Asp Leu Pro Ser Val Thr Ile Ser Glu Lys Leu
          50          55          60
Gln Lys Asp Ile Lys Asp Leu Gly Gly Arg Val Glu Glu Phe Leu Ser
 65          70          75          80
Lys Asp Ile Ser Tyr Leu Ile Ser Asn Lys Lys Glu Ala Lys Phe Ala
          85          90          95
Gln Thr Leu Gly Arg Ile Ser Pro Val Pro Ser Pro Glu Ser Ala Tyr
          100          105          110
Thr Ala Glu Thr Thr Ser Pro His Pro Ser His Asp Gly Ser Ser Phe
          115          120          125
Lys Ser Pro Asp Thr Val Cys Leu Ser Arg Gly Lys Leu Leu Val Glu
          130          135          140
Lys Ala Ile Lys Asp His Asp Phe Ile Pro Ser Asn Ser Ile Leu Ser
145          150          155          160
Asn Ala Leu Ser Trp Gly Val Lys Ile Leu His Ile Asp Asp Ile Arg
          165          170          175
Tyr Tyr Ile Glu Gln Lys Lys Lys Glu Leu Tyr Leu Leu Lys Lys Ser
          180          185          190
Ser Thr Ser Val Arg Asp Gly Gly Lys Arg Val Gly Ser Gly Ala Gln
          195          200          205
Lys Thr Arg Thr Gly Arg Leu Lys Lys Pro Phe Val Lys Val Glu Asp
          210          215          220
Met Ser Gln Ser Pro Ala Val His Leu Met
225          230          234

```

<210> 3

<211> 2780

<212> DNA

<213> Homo sapiens

<400> 3

```

AATTCGGCAC GAGCTCTCTG AGGCTGCGCC AAGACCTGAA GCGGCGGACC GAGAGCCCCG 60
GTCTGAGACT GAGAGAGCAA CGGAATGGAG GCGGGGTAGA GGCGGAAACA CAACCTGCAG 120
GGCCAGAGCG AGGCGCGAGA AGGACGGCGG CGTGAGGGGG CGGGGCGCGC AGCGCGAGAA 180
GGCAGGCACG AGGGGCGAGC GCGAGGCGGG GCACGGCGCG TGGCGTGAGA CGGGGCGGGG 240
CGCGCGTATC GCGCCGCGG CCGCGTGACG CGTTTTCAAA TCTTCAACCG CCGCAGCCCA 300
CTCGTTTGTG CTTTGCGCCT TCCTCCTCCG CGCCTTGGAG CCGGATCCGG CCCC GGAAAC 360
CCGACCTGCA GACGCGGTAC CTCTACTGCG TAGAGGCCGT AGCTGGCGGA AGGAGAGAGG 420
CGGCCGTCCT GTCAACAGGC CGGGGGAAGC CGTGCTTTTC CGGCTGCCCC GTGCGACACT 480
TTCTCCGGAC CCAGCATGTA GGTGCCGGGC GACTGCCATG AACTCCGGAG CCATGAGGAT 540
CCACAGTAAA GGACATTTCC AGGGTGGAAT CCAAGTCAAA AATGAAAAAA ACAGACCATC 600
TCTGAAATCT CTGAAAACTG ATAACAGGCC AGAAAAATCC AAATGTAAGC CACTTTGGGG 660
AAAAGTATTT TACCTTGACT TACCTTCTGT CACCATATCT GAAAAACTTC AAAAGGACAT 720
TAAGGATCTG GGAGGGCGAG TTGAAGAATT TCTCAGCAAA GATATCAGTT ATCTTATTTT 780
AAATAAGAAG GAAGCTAAAT TTGCACAAAC CTTGGGTCGA ATTTCTCCTG TACCAAGTCC 840

```

20d

AGAATCTGCA	TATACTGCAG	AAACCACTTC	ACCTCATCCC	AGCCATGATG	GAAGTTCATT	900
TAAGTCACCA	GACACAGTGT	GTTTAAGCAG	AGGAAAATTA	TTAGTTGAAA	AAGCTATCAA	960
GGACCATGAT	TTTATTCCTT	CAAATAGTAT	ATTATCAAAT	GCCTTGTCAT	GGGGAGTAAA	1020
AATTCTTCAT	ATTGATGACA	TTAGATACTA	CATTGAACAA	AAGAAAAAAG	AGTTGTATTT	1080
ACTCAAGAAA	TCAAGTACTT	CAGTAAGAGA	TGGGGGCAAA	AGAGTTGGTA	GTGGTGCACA	1140
AAAAACAAGA	ACAGGAAGAC	TCAAAAAGCC	TTTTGTAAAG	GTGGAAGATA	TGAGCCAACT	1200
TTATAGGCCA	TTTTATCTTC	AGCTGACCAA	TATGCCTTTT	ATAAATTATT	CTATTCAGAA	1260
GCCCTGCAGT	CCATTTGATG	TAGACAAGCC	ATCTAGTATG	CAAAAGCAAA	CTCAGGTTAA	1320
ACTAAGAATC	CAAACAGATG	GCGATAAGTA	TGGTGAAC	TCAATTCAAC	TCCAGTTGAA	1380
AGAGAAGAAG	AAAAAAGGAT	ATTGTGAATG	TTGCTTGCAG	AAATATGAAG	ATCTAGAAAC	1440
TCACCTTCTA	AGTGAGCAAC	ACAGAACTT	TGCACAGAGT	AACCAGTATC	AAGTTGTTGA	1500
TGATATTGTA	TCTAAGTTAG	TTTTTGACTT	TGTGGAATAT	GAAAAGGACA	CACCTAAAAA	1560
GAAAAGAATA	AAATACAGTG	TTGGATCCCT	TTCTCCTGTT	TCTGCAAGTG	TCCTGAAAAA	1620
GACTGAACAA	AAGGAAAAAG	TGGAATTGCA	ACATATTTCT	CAGAAAGATT	GCCAGGAAGA	1680
TGATACAACA	GTGAAGGAGC	AGAATTTCT	GTATAAAGAG	ACCCAGGAAA	CTGAAAAAAA	1740
GCTCCTGTTT	ATTTTCAGAGC	CCATCCCCCA	CCCTTCAAAT	GAATTGAGAG	GGCTTAATGA	1800
GAAAATGAGT	AATAAATGTT	CCATGTTAAG	TACAGCTGAA	GATGACATAA	GACAGAATTT	1860
TACACAGCTA	CCTCTACATA	AAAACAAACA	GGAATGCATT	CTTGACATTT	CCGAACACAC	1920
ATTAAGTGAA	AATGACTTAG	AAGAACTAAG	GGTAGATCAC	TATAAATGTA	ACATACAGGC	1980
ATCTGTACAT	GTTTCTGATT	TCAGTACAGA	TAATAGTGGA	TCTCAACCAA	AACAGAAGTC	2040
AGATACTGTG	CTTTTTCCAG	CAAAGGATCT	CAAGGAAAAG	GACCTTCATT	CAATATTTAC	2100
TCATGATTCT	GGTCTGATAA	CAATAAACAG	TTCACAAGAG	CACCTAACTG	TTCAGGCAAA	2160
GGCTCCATTC	CATACTCCTC	CTGAGGAACC	CAATGAATGT	GACTTCAAGA	ATATGGATAG	2220
TTTACCTTCT	GGTAAAATAC	ATCGAAAAGT	GAAAATAATA	TTAGGACGAA	ATAGAAAAGA	2280
AAATCTGGAA	CCAAATGCTG	AATTTGATAA	AAGAACTGAA	TTTATTACAC	AAGAAGAAAA	2340
CAGAATTTGT	AGTTCACCGG	TACAGTCTTT	ACTAGACTTG	TTTCAGACTA	GTGAAGAGAA	2400
ATCAGAATTT	TTGGGTTTCA	CAAGCTACAC	AGAAAAGAGT	GGTATATGCA	ATGTTTTAGA	2460
TATTTGGGAA	GAGGAAAATT	CAGATAATCT	GTAAACAGCG	TTTTTCTCGT	CCCCTTCAAC	2520
TTCTACATTT	ACTGGCTTTT	AGAATTTAAA	AAATGCATAC	TTTTTCAGAAG	TGATAAGGAT	2580
CATATTCTTG	AAATTTTAT	AAATATGTAT	GGAAATTCTT	AGGATTTTTT	TACCAGCTTT	2640
GTTTACAGAC	CCAAATGTAA	ATATTAAAAA	TAAATATTTG	CAATTTTCTA	CAGAATTGAA	2700
TACCTGTAA	AGAAAAATTA	CAGAATAAAC	TTGTGACTGG	TCTTGTTTAA	CATTAAAAAA	2760
AAAAAAAAAA	AAACTCGAG					2780

<210> 4

<211> 2719

<212> DNA

<213> Homo sapiens

<400> 4

AATTCGGCAC	GAGCTCTCTG	AGGCTGCGCC	AAGACCTGAA	GCGGCGGACC	GAGAGCCCGG	60
GTCTGAGACT	GAGAGAGCAA	CGGAATGGAG	GCGGGGTAGA	GGCGGAAACA	CAACCTGCAG	120
GGCCAGAGCG	AGGCGCGAGA	AGGACGGCGG	CGTGAGGGGG	CGGGGCGCGC	AGCGCGAGAA	180
GGCAGGCACG	AGGGGCGAGC	GCGAGGCGGG	GCACGGCGCG	TGGCGTGAGA	CGGGGCGGGG	240
CGCGCGTATC	GGCGCCGCGG	CCGCGTGACG	CGTTTTTCAA	TCTTCAACCG	CCGCAGCCCA	300
CTCGTTTGTG	CTTTGCGCCT	TCCTCCTCCG	CGCCTTGAG	CCGGATCCGG	CCCCGGAAAC	360
CCGACCTGCA	GACGCGGTAC	CTCTACTGCG	TAGAGGCCGT	AGCTGGCGGA	AGGAGAGAGG	420
CGGCCGTCCT	GTCAACAGGC	CGGGGGAAGC	CGTGCTTTTC	CGGCTGCCCC	GTGCGACACT	480
TTCTCCGGAC	CCAGCATGTA	GGTGCCGGGC	GACTGCCATG	AACTCCGGAG	CCATGAGGAT	540
CCACAGTAAA	GGACATTTCC	AGGGTGGAAT	CCAAGTCAAA	AATGAAAAAA	ACAGACCATC	600
TCTGAAATCT	CTGAAAACCTG	ATAACAGGCC	AGAAAAATCC	AAATGTAAGC	CACTTTGGGG	660
AAAAGTATTT	TACCTTGACT	TACCTTCTGT	CACCATATCT	GAAAAACTTC	AAAAGGACAT	720
TAAGGATCTG	GGAGGGCGAG	TTGAAGAATT	TCTCAGCAAA	GATATCAGTT	ATCTTATTTT	780
AAATAAGAAG	GAAGCTAAAT	TTGCACAAAC	CTTGGGTCGA	ATTTCTCCTG	TACCAAGTCC	840
AGAATCTGCA	TATACTGCAG	AAACCACTTC	ACCTCATCCC	AGCCATGATG	GAAGTTCATT	900
TAAGTCACCA	GACACAGTGT	GTTTAAGCAG	AGGAAAATTA	TTAGTTGAAA	AAGCTATCAA	960

GGACCATGAT	TTTATTCCTT	CAAATAGTAT	ATTATCAAAT	GCCTTGTCAT	GGGGAGTAAA	1020
AATTCTTCAT	ATTGATGACA	TTAGATACTA	CATTGAACAA	AAGAAAAAAG	AGTTGTATTT	1080
ACTCAAGAAA	TCAAGTACTT	CAGTAAGAGA	TGGGGGCAAA	AGAGTTGGTA	GTGGTGCACA	1140
AAAAACAAGA	ACAGGAAGAC	TCAAAAAGCC	TTTTGTAAAG	GTGGAAGATA	TGAGCCAAAG	1200
CCCTGCAGTC	CATTTGATGT	AGACAAGCCA	TCTAGTATGC	AAAAGCAAAC	TCAGGTAAAA	1260
CTAAGAATCC	AAACAGATGG	CGATAAGTAT	GGTGGAACCT	CAATTCAACT	CCAGTTGAAA	1320
GAGAAGAAGA	AAAAAGGATA	TTGTGAATGT	TGCTTGACAG	AATATGAAGA	TCTAGAAACT	1380
CACCTTCTAA	GTGAGCAACA	CAGAAACTTT	GCACAGAGTA	ACCAGTATCA	AGTTGTTGAT	1440
GATATTGTAT	CTAAGTTAGT	TTTTGACTTT	GTGGAATATG	AAAAGGACAC	ACCTAAAAAG	1500
AAAAGAATAA	AATACAGTGT	TGGATCCCTT	TCTCCTGTTT	CTGCAAGTGT	CCTGAAAAAG	1560
ACTGAACAAA	AGGAAAAAGT	GGAATTGCAA	CATATTTCTC	AGAAAGATTG	CCAGGAAGAT	1620
GATACAACAG	TGAAGGAGCA	GAATTTCTCT	TATAAAGAGA	CCCAGGAAAC	TGAAAAAAG	1680
CTCCTGTTTA	TTTCAGAGCC	CATCCCCCAC	CCTTCAAATG	AATTGAGAGG	GCTTAATGAG	1740
AAAATGAGTA	ATAAATGTTC	CATGTTAAGT	ACAGCTGAAG	ATGACATAAG	ACAGAATTTT	1800
ACACAGCTAC	CTCTACATAA	AAACAAACAG	GAATGCATTC	TTGACATTTT	CGAACACACA	1860
TTAAGTGAAA	ATGACTTAGA	AGAACTAAGG	GTAGATCACT	ATAAATGTAA	CATACAGGCA	1920
TCTGTACATG	TTTCTGATTT	CAGTACAGAT	AATAGTGGAT	CTCAACCAAA	ACAGAAGTCA	1980
GATACTGTGC	TTTTTCCAGC	AAAGGATCTC	AAGGAAAAGG	ACCTTCATTC	AATATTTACT	2040
CATGATTCTG	GTCTGATAAC	AATAAACAGT	TCACAAGAGC	ACCTAACTGT	TCAGGCAAAG	2100
GCTCCATTCC	ATACTCCTCC	TGAGGAACCC	AATGAATGTG	ACTTCAAGAA	TATGGATAGT	2160
TTACCTTCTG	GTAAAATACA	TCGAAAAGTG	AAAATAATAT	TAGGACGAAA	TAGAAAAGAA	2220
AATCTGGAAC	CAAATGCTGA	ATTTGATAAA	AGAACTGAAT	TTATTACACA	AGAAGAAAAC	2280
AGAATTTGTA	GTTCAACGGT	ACAGTCTTTA	CTAGACTTGT	TTCAGACTAG	TGAAGAGAAA	2340
TCAGAATTTT	TGGGTTTCAC	AAGCTACACA	GAAAAGAGTG	GTATATGCAA	TGTTTTTAGAT	2400
ATTTGGGAAG	AGGAAAATTC	AGATAATCTG	TTAACAGCGT	TTTTCTCGTC	CCCTTCAACT	2460
TCTACATTTA	CTGGCTTTTA	GAATTTAAAA	AATGCATACT	TTTCAGAAGT	GATAAGGATC	2520
ATATTCTTGA	AATTTTTATA	AATATGTATG	GAAATTCTTA	GGATTTTTTT	ACCAGCTTTG	2580
TTTACAGACC	CAAATGTAAA	TATTAAAAAT	AAATATTTGC	AATTTTCTAC	AGAATTGAAT	2640
ACCTGTTAAA	GAAAAATTAC	AGAATAAACT	TGTGACTGGT	CTTGTTTTAC	ATTAAAAAAA	2700
AAAAAAAAAA	AAACTCGAG					2719

CLAIMS:

1. A human protein comprising the amino acid sequence of SEQ ID NO: 1.
2. A human protein comprising the amino acid sequence of SEQ ID NO: 2.
3. A cDNA encoding the human protein of claim 1 or 2.
4. A cDNA which comprises the base sequence of SEQ ID NO: 3.
5. A cDNA which comprises the base sequence of SEQ ID NO: 4.
6. A recombinant vector comprising the cDNA of claim 3.
7. A recombinant vector comprising the cDNA of claim 4.
8. A recombinant vector comprising the cDNA of claim 5.
9. An antibody against the human protein of claim 1.
10. An antibody against the human protein of claim 2.
11. A method for promoting the proliferation of cells *in vitro*, which comprises introducing the cDNA of claim 3 together with an expression regulatory sequence into the cells.
12. A method for promoting the proliferation of cells *in vitro*, which comprises introducing the cDNA of claim 4 together with an expression-regulatory sequences into the cells.
13. A method for promoting the proliferation of cells *in vitro*, which comprises introducing the cDNA of claim 5 together with an expression regulatory sequence into the cells.

14. A method for suppressing the proliferation of cells *in vitro*, which comprises introducing the antibody of claim 9 into the cells.
15. A method for suppressing the proliferation of cells *in vitro*, which comprises introducing the antibody of claim 10 into the cells.
16. Use of the cDNA of claim 3 together with an expression-regulatory sequence for promoting the proliferation of cells.
17. Use of the cDNA of claim 4 together with an expression-regulatory sequence for promoting the proliferation of cells.
18. Use of the cDNA of claim 5 together with an expression-regulatory sequence for promoting the proliferation of cells.
19. Use of an antibody as defined in claim 9 for suppressing the proliferation of cells.
20. Use of an antibody as defined in claim 10 for suppressing the proliferation of cells.

Application number/numéro de demande: 2,348,732

Figures: 1, 2, 10 A, 10 B, 17 A to 17 F, 20

Pages: 1/20, 2/20, 10/20, 17/20, 20/20

Unscannable Item(s) received with this application.

To inquire if you can order a copy of the unscannable item(s),

Please visit the CIPO Website at [HTTP://CIPO.GC.CA](http://CIPO.GC.CA)

Item(s) ne pouvant être balayés.

Documents reçus avec cette demande ne pouvant être balayés.


Pour vous renseigner si vous pouvez commander

une copie des items ne pouvant être balayés,

veuillez visiter le site web de l'OPIC au [HTTP://CIPO.GC.CA](http://CIPO.GC.CA)


3/20

Fig. 3



4/20

Fig.4




1	10	20	30	40	50	60
MNSGAMRIHSGHFGGGIQVKNRPSLKS <u>LKTDNRPEKSKCKPLWGKVLYLDLPSVTI</u>						
						Dbf4 motif-N
61	70	80	90	100	110	120
<u>SEKLOKDIKDLGGRVEEFLSKDISYLLSNKKEAKFAOTLGRISPVPSPESAYTAETTS</u> PH						
121	130	140	150	160	170	180
PSHDGSSFRSPDTVCLSRGKLLVEKAIKDHDFIPSNLSILSNALSWGKILHIDDIRYYIE						
181	190	200	210	220	230	240
QKKKELYLLKKSSTSVRDGGKRVGSGAQKTRTGRLKKPFVKVEDMSQLYRPFYLQLTNMP						
241	250	260	270	280	290	300
FINYSIQKPCSPFDVDRPSSMQKOTQVKLRIOTDGDKYGGT <u>SIQLOLKEKKKRGYCECCL</u>						
						Dbf4 motif-C
301	310	320	330	340	350	360
<u>QKYEDLETHLLSEQHRNFAQSNQYQVVDDIVSKLVDFVEYEKDTPKKKRIKYSVGSLS</u> P						
361	370	380	390	400	410	420
VSASVLKKTEQKEKVELQHISQKDCQEDDTTVKEQNFLYKETQETEKLLFISEPIPHPS						
421	430	440	450	460	470	480
NELRGLNEKMSNKC S MLSTAEDDIRQNFTQLPLHKNKQECILDISEHTLSENDLEELRVD						
481	490	500	510	520	530	540
HYKCNIQASVHVSDFDSTDNSSGSQPKQKSOTVLFPAKDLKEKDLHSIFTHDSGLITINSSQ						
541	550	560	570	580	590	600
EHLTVQAKAPFHTPPEEPNECDFKNMDSLPSGKIHRKVKIILGRNRKENLEPNAEFOKRT						
601	610	620	630	640	650	660
EFITQEENRICSSPVQSLDLFQTSEEKSEFLGFTSYTEKSGICNVLDIWEENE S DNLLT						
661	670	674				
AFFSSPSTSTFTGF*						

H37 263: KQTQVKLRIQTDGDKYGGT SIQLQLKEK KKKGYCEGGLQKYEDLETHL LSEQHRNFAQSN 322
mu-H37 : KQAQPKLRINMDGDKC-GIPVQLQLKEKRKKGYCEGGLQKYEDLETHL LSEQHRNFAQSN
Dm-H37 : PSLQELKKQSAIPNSPRSNCREPIDSSKQCGVCEICKLEYDILNIHL LSKDHLEFAKNS
Dbf4 619: KKSTSTNVTLHFNAQTACTAQPVKKETVKNSGYCHNCRWKYESLEQHTVSEKHLSEAE-N 677
* * * * *

7/20


Fig. 7



8/20


Fig. 8

β -galactosidase
Activity (Unit)




9/20

Fig.9




11/20

Fig. 11




12/20

Fig.12




13/20

Fig.13



14/20


Fig.14




15/20

Fig.15

1 (G2/M)



2 (6h)



3 (12h)






4 (18h)




16/20

Fig. 16




18/20


Fig. 18

%BrdU-Positive
Cells

19/20

Fig. 19





Dbf4 motif-N

H37	32:	LKTDNPFLEKSNCKPLWGKVEYLDIPSVTISEKLOKDTKDLGGRVEEFLSKDISYLTISNKK	91
mu-H37	:	LKADNPFLEKSNCKPLWGKVEYLDIPSVTISEKLOKDTKDLGGRVEEFLSKDISYFVSNKK	
Dm-H37	:	TPPKVKVVKSK-RPLCHFKFYLLICDHQLAKRIESDIKALGGHLEFFLSDDITHFVTDKP	
		*** ** ***** *** ** * *** ** *	
huDbf4N	92:	EAKFAQT	98
muDbf4N	:	EAKYAQT	
DmDbf4N	:	EVIGGTS	
		*	

Dbf4 motif-C

H37	263:	KQTGVKLRIQTDGDKYGGTSIQLQLKEKRRKGYCECCLOKYEDLETHLSEQRNFAQSN	322
mu-H37	:	KQAQPKLRINMDGDKC-GIPVQLQLKEKRRKGYCECCLOKYEDLETHLSEQRNFAQSN	
Dm-H37	:	PSLQELKKQSAIPNSPRSNCREPIDSSKQCGVCEICKLEYDILNIHLQSKDPELFAKNS	
Dbf4	619:	KKSTSTNVTLHFNAQTACIAQPVKKETVKNSSGYCHNCRVKYESLEQHIVSEKHLSEAE-N	677
		* * * * *	